Amlodipine as add-on to Olmesartan in Hypertension
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00220220|
Recruitment Status : Completed
First Posted : September 22, 2005
Last Update Posted : December 24, 2018
|Condition or disease||Intervention/treatment||Phase|
|Essential Hypertension||Drug: olmesartan medoxomil Drug: amlodipine||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||429 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Efficacy and Safety of Amlodipine Used as add-on Therapy in Moderately to Severely Hypertensive Patients Not Adequately Controlled by Olmesartan Medoxomil 20 mg Monotherapy|
|Study Start Date :||April 2005|
|Actual Study Completion Date :||April 2007|
- Mean change in trough sitting diastolic blood pressure (dBP) assessed by conventional BP measurements after 8 weeks of double-blind treatment.
- Mean change in trough sitting sBP and mean BP daytime, nighttime and 24h ABPM after 8 weeks of double-blind treatment.
- Responder rate, defined as number (%) of patients achieving BP goals during 8 weeks of double-blind treatment.
- Safety and tolerability
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00220220
|Principal Investigator:||Peter Brommer, MD|